We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+17.63%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$808M
AUM Growth
+$311M
(+63%)
Cap. Flow
+$255M
Cap. Flow
% of AUM
31.62%
Top 10 Holdings %
Top 10 Hldgs %
37.23%
Holding
104
New
33
Increased
25
Reduced
12
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$46.9M |
| 2 |
Zimmer Biomet
ZBH
|
+$40.8M |
| 3 |
McKesson
MCK
|
+$27.7M |
| 4 |
Tenet Healthcare
THC
|
+$16.5M |
| 5 |
Boston Scientific
BSX
|
+$16.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stryker
SYK
|
+$14.3M |
| 2 |
Teleflex
TFX
|
+$11.7M |
| 3 |
Cardinal Health
CAH
|
+$11.5M |
| 4 |
Biogen
BIIB
|
+$11.1M |
| 5 |
Idexx Laboratories
IDXX
|
+$10M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.35% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
CRISPR Therapeutics
CRSP
$5.16B
| $5.61M | 0.7% |
100,000
| – | – |
|
52
Privia Health
PRVA
$2.82B
| $5.22M | 0.65% |
+200,000
| New | +$5.28M |
|
53
Envista
NVST
$4.61B
| $5.08M | 0.63% |
150,000
-2,000
| -1% | -$70.6K |
|
54
Teladoc Health
TDOC
$1.25B
| $5.06M | 0.63% |
+200,000
| New | +$5.03M |
|
55
Cencora
COR
$63.2B
| $5M | 0.62% |
+26,000
| New | +$4.5M |
|
|
FOLD
56
DELISTED
Amicus Therapeutics
FOLD
| $4.86M | 0.6% |
387,000
+82,000
| +27% | +$973K |
|
|
LBPH
57
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $4.39M | 0.54% |
598,000
+16,000
| +3% | +$121K |
|
|
CCRN
58
DELISTED
Cross Country Healthcare
CCRN
| $4.35M | 0.54% |
+155,000
| New | +$3.85M |
|
59
BioMarin Pharmaceuticals
BMRN
$13.4B
| $4.33M | 0.54% |
50,000
-50,000
| -50% | -$4.71M |
|
60
Dentsply Sirona
XRAY
$2.33B
| $4M | 0.5% |
+100,000
| New | +$3.98M |
|
61
BioNTech
BNTX
$23.3B
| $3.89M | 0.48% |
+36,000
| New | +$4.05M |
|
|
SAGE
62
DELISTED
Sage Therapeutics
SAGE
| $3.76M | 0.47% |
80,000
-165,000
| -67% | -$8.21M |
|
63
Prothena Corp
PRTA
$468M
| $3.55M | 0.44% |
+52,000
| New | +$3.35M |
|
|
AKRO
64
DELISTED
Akero Therapeutics
AKRO
| $3.27M | 0.4% |
70,000
| – | – |
|
|
WBA
65
CALL
DELISTED
Walgreens Boots Alliance
WBA
| $2.85M | 0.35% |
+100,000
| New | +$3.26M |
|
66
CALL
uniQure
QURE
$3.12B
| $2.29M | 0.28% |
+200,000
| New | +$3.79M |
|
67
Supernus Pharmaceuticals
SUPN
$2.8B
| $2.25M | 0.28% |
75,000
-50,000
| -40% | -$1.75M |
|
68
Keros Therapeutics
KROS
$210M
| $2.09M | 0.26% |
52,000
+2,000
| +4% | +$87.7K |
|
69
Protagonist Therapeutics
PTGX
$9.59B
| $2.07M | 0.26% |
+75,000
| New | +$1.88M |
|
70
Allogene Therapeutics
ALLO
$742M
| $2.05M | 0.25% |
412,000
+7,000
| +2% | +$37.9K |
|
71
Elanco Animal Health
ELAN
$11.4B
| $2.01M | 0.25% |
+200,000
| New | +$1.86M |
|
|
TERN
72
DELISTED
Terns Pharmaceuticals
TERN
| $1.57M | 0.2% |
180,000
+80,000
| +80% | +$932K |
|
73
Dyne Therapeutics
DYN
$4.94B
| $698K | 0.09% |
62,000
+5,000
| +9% | +$59K |
|
74
Acadia Healthcare
ACHC
$2.9B
| – | – |
-61,000
| Closed | -$4.41M |
|
75
CALL
Aclaris Therapeutics
ACRS
$868M
| – | – |
-250,000
| Closed | -$2.02M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q2 2023 Portfolio in Review
As of Q2 2023, Integral Health Asset Management held 104 positions worth $808M, up 63% from $496M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Integral Health Asset Management deployed $255M of net new capital in Q2 2023, opening 33 new positions and adding to 25 existing holdings. Its largest new stake was Cigna: 180,000 shares worth $50.5M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Consumer Staples.
On the sell side, the largest reduction was Elevance Health, an estimated $9.69M trimmed.
- Integral Health Asset Management's largest Q2 2023 buy was Cigna: 180,000 shares worth $50.5M.
- Integral Health Asset Management added most to Boston Scientific in Q2 2023, an estimated $16.4M increase.
- Integral Health Asset Management's biggest Q2 2023 reduction was Elevance Health, cutting an estimated $9.69M.
- Integral Health Asset Management fully exited Stryker in Q2 2023, selling an estimated $14.3M.
- Integral Health Asset Management's ten largest holdings make up 37% of its $808M portfolio in Q2 2023.
- Integral Health Asset Management opened 33 new positions and closed 31 in Q2 2023.
- Integral Health Asset Management's portfolio value rose 63% quarter-over-quarter to $808M.
Based on Integral Health Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.